Financial Performance - Sino Medical reported no cash dividends for 2022 due to adverse impacts from the centralized procurement policy for coronary stents, prioritizing future development needs[6]. - The company did not achieve profitability at the time of its listing, indicating ongoing investment in product development and market expansion[5]. - The board of directors approved a profit distribution plan that reflects the company's current operational challenges and future funding requirements[6]. - Sino Medical's financial report received a standard unqualified audit opinion from its accounting firm, ensuring the accuracy of its financial statements[6]. - The company achieved total operating revenue of CNY 192,854,227.69 in 2022, a decrease of 0.77% compared to the previous year[26]. - The net profit attributable to shareholders was CNY -162,381,785.82, a decline of 24.18% year-on-year[26]. - The net cash flow from operating activities was CNY -111,312,741.89, down 85.11% compared to the previous year, primarily due to a decrease in revenue and delayed customer payments[27]. - Basic and diluted earnings per share were both CNY -0.40, a decrease of 25.00% from the previous year[24]. - The company's R&D expenditure accounted for 107.51% of operating revenue, an increase of 12.14 percentage points year-on-year[24]. - The gross profit margin decreased due to a significant drop in product prices and low capacity utilization[26]. - Total assets at the end of 2022 were CNY 1,067,613,744.66, a decrease of 3.22% from the previous year[23]. - The company's net assets attributable to shareholders were CNY 847,084,284.58, down 8.70% year-on-year[23]. Research and Development - Sino Medical is actively engaged in research and development of new products, particularly in the field of interventional medical devices[15]. - The company invested a total of 207 million RMB in R&D throughout the year, an increase of 11.86% year-on-year, accounting for 107.51% of the 2022 operating revenue[43]. - The company holds 185 global invention patents across various countries, enhancing its competitive edge in the market[43]. - The company launched three innovative products in the neurointervention field, establishing a leading position in this sector[42]. - The company has obtained 6 domestic medical device registration certificates and 1 FDA (510k) certification during the reporting period[43]. - The company published 4 papers in core journals, contributing to its reputation in the medical device industry[43]. - The company has established a comprehensive core technology system for interventional medical devices, focusing on cardiovascular and cerebrovascular diseases, supporting sustained business growth[105]. - The company has developed a series of specialized automated production equipment and operates over 25,000 square meters of R&D and production space, including a 9,000 square meter cleanroom[109]. Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its product offerings to meet growing healthcare demands[15]. - The company is advancing its internationalization strategy, with product registrations in over 10 countries including the USA, Europe, and Southeast Asia[50]. - The company is exploring opportunities for market expansion and potential mergers and acquisitions to enhance its competitive edge[55]. - The company aims to improve patient outcomes through advanced medical technologies and innovative product designs[55]. - The company is committed to maintaining high standards of product quality and regulatory compliance in all its markets[55]. - The company aims to continuously innovate and meet diverse clinical needs through sustained R&D investment and breakthrough innovations[67]. - The company is focusing on three key interventional treatment areas: coronary intervention, neuro intervention, and structural heart disease, to diversify its business[179]. - The company plans to accelerate its international strategy, including seeking innovation and collaboration globally, and enhancing its presence in overseas markets[180]. Operational Risks and Challenges - The company has outlined various operational risks in its annual report, emphasizing the importance of risk management strategies[5]. - The company faces risks of substantial revenue decline and continued losses due to high production costs and potential underperformance in sales volume[115]. - The company is at risk of new product development failures or delays, which could hinder revenue growth and profitability[116]. - The company may experience talent loss if it fails to provide competitive compensation and development opportunities, impacting its operational capabilities[117]. - The company is exposed to risks from centralized procurement policies leading to price reductions for its coronary and neuro-interventional products[120]. - The company reported a continuous loss in 2022, with ongoing risks of sustained losses in 2023 despite participation in procurement programs[128]. Product Portfolio and Innovation - The company has a diverse product portfolio including coronary stents, balloon catheters, and neurovascular devices, with several products being industry leaders both domestically and internationally[55]. - The company has developed a new generation of magnesium alloy biodegradable stents, which maintain mechanical support for 3 to 6 months post-implantation and fully degrade within one year[80]. - The company has established an automated intelligent technology platform to enhance production consistency and precision in testing data[80]. - The company has made significant breakthroughs in neuro intervention, with the world's first self-expanding drug-eluting stent entering clinical stages and completing clinical enrollment in February 2023[84]. - The company successfully entered two new products into the national coronary stent procurement program, achieving selection by over 1,000 hospitals, marking a significant milestone for its coronary stent products[184]. Financial Outlook and Projections - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2022, representing a growth of 20% year-over-year[200]. - The company has provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion[200]. - New product launches are expected to contribute an additional 300 million in revenue, with a focus on innovative medical technologies[200]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 200 million earmarked for this purpose[200]. - The company aims to improve operational efficiency, targeting a reduction in costs by 5% through streamlined processes[200].

证券代码：688108 证券简称：赛诺医疗 公告编号：2023-024 一、 说明会类型 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司 关于召开 2022 年度业绩说明会的公告 本次投资者说明会以视频直播和网络文字互动形式召开，公司将针对 2022 年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （网址：http://roadshow.sseinfo.com/） 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）于 2023 年 4 月 27 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年 度经营成果、财务状况，公司计划于 2023 年 05 月 10 日下午 15:00-16:30 举行 2022 年 度业绩说明会，就投资者关心的问题进行交流。 会议召开时间：2023 年 05 月 10 日(星期三)下午 15:00-16 ...

证券代码：688108 证券简称：赛诺医疗 公告编号：2023-009 赛诺医疗科学技术股份有限公司 关于参加 2022 年度医疗器械专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （http://roadshow.sseinfo.com/） 投资者可于 2023 年 4 月 27 日(星期四)17:00 前通过公司邮箱（ir@sinomed.com）、 投资者关系电话（010-80482240）、传真等方式将需要了解和关注的问题提前提供给 公司。公司将在文字互动环节对投资者普遍关注的问题进行回答。 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"）将于2023年 4月27日发布公司2022年年度报告，为便于广大投资者更及时全面深入地了解公司2022 年度的经营成果、财务状况和发展理念，公司计划于2023年04月28日参加上海证券交易 所主办的2022年度医疗器械专场集体业绩说明会，就投资者关心的问题进行线上交流。 一、 说明会类型 本次业绩说明会将以视频和网络互动形式 ...

证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | --- | |----------------|--------------------------------------------|-------------------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | □特定对象调研 □分析师会议 | | | | 投资者关系 | | □媒体采访 业绩说明会 | | | | 活动类别 | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | | □其他 | | | | | 参与单位名称 | 网上投资者 | | | | | 及人员姓名 | | | | | | | 时 间 2022 年 5 月 16 | 日 9:00-10:00 | | | | 接待人员姓名 | 地 点 上证路演中心 | ...

公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 重要内容提示： 2022 年第三季度报告 证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期末 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | 比上年同期增减 | | | | 动幅度(%) | | 变动幅度(%) | | 营业收入 | 55,624,497.05 | 30.88 | 165,927,252.95 | 36.98 | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥110,302,755.90, representing a 40.28% increase compared to ¥78,633,119.10 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was -¥71,234,762.46, an improvement of 12.64% from -¥81,542,212.35 in the previous year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥73,614,639.21, showing an 11.63% improvement from -¥83,299,852.62 year-on-year[17]. - The net cash flow from operating activities was -¥48,485,199.62, which is a decline of 95.43% compared to -¥24,809,916.71 in the same period last year[17]. - The net assets attributable to shareholders at the end of the reporting period were ¥859,100,349.51, a decrease of 7.41% from ¥927,836,465.08 at the end of the previous year[17]. - Total assets at the end of the reporting period were ¥1,065,252,701.61, down 3.43% from ¥1,103,085,987.51 at the end of the previous year[17]. - Basic earnings per share for the reporting period is -0.17 yuan, an improvement of 15% compared to -0.20 yuan in the same period last year[18]. - Operating revenue increased by 40.28% year-on-year, reaching 45.7045 million yuan, primarily driven by a 57.59% increase in coronary and other business revenues[18]. - Net profit attributable to shareholders grew by 12.64% year-on-year, influenced by the significant increase in operating revenue and a 20.07% rise in total operating costs[19]. - The weighted average return on equity decreased by 0.07 percentage points to -7.98% compared to the same period last year[21]. Research and Development - Research and development expenses accounted for 97.00% of operating revenue, a decrease of 12.35 percentage points from 109.35% in the previous year[18]. - The company achieved a cumulative R&D investment of 107 million yuan in the first half of 2022, an increase of 24.44% year-on-year, representing 97% of the operating revenue for the same period[39]. - The company has developed 8 key technologies and 29 product pipelines, with 5 new invention patents and 16 other intellectual property rights granted during the reporting period[40]. - The company filed for a total of 9 new intellectual property applications during the reporting period, bringing the cumulative total to 449 applications[54]. - The company has increased its R&D personnel to 177, representing 26.26% of the total workforce, up from 125 and 23.95% in the same period last year[82]. - Total compensation for R&D personnel reached 2,570.7 million, compared to 1,723.79 million in the previous year, reflecting a significant increase in investment in talent[82]. - The average salary for R&D personnel rose to 14.52 million from 13.79 million year-on-year[82]. Product Development and Innovation - The company continues to focus on expanding its product offerings and enhancing its market presence in the medical device sector, supported by favorable government policies[27]. - Sino Medical focuses on high-end interventional medical device R&D, production, and sales, covering key areas such as cardiovascular, neurovascular, and structural heart disease interventions[28]. - The company’s product pipeline includes advanced devices for coronary, neurovascular, and structural heart disease interventions, leveraging existing core technologies[30]. - The new generation coronary drug-eluting stent HT Supreme, approved in December 2020, is the only domestic product with a 5.0mm large specification and has received CE certification and FDA acceptance[34]. - The NOVA intracranial drug-eluting stent, launched in July 2021, is the world's first specifically designed for intracranial artery stenosis treatment, enhancing patient safety and reducing the risk of re-stenosis[36]. - The company’s negative pressure suction pump, approved in April 2022, is designed to improve surgical efficiency and is compatible with various suction devices[37]. - The company is developing a retractable, dual-stent, self-locking intervention mitral valve replacement technology, with over 30 patents granted globally[47]. - The company’s coated mesh stent, the only one of its kind in China, is expected to start clinical enrollment by the end of 2022[46]. - The company has developed a new intracranial drug balloon system, which is expected to have a significant development space and broad market prospects[72]. Market Outlook and Strategy - The coronary intervention market in China is the most mature segment, with significant room for import substitution and rapid growth driven by local manufacturers and increased market penetration[28]. - The neurovascular intervention market in China is still in its early stages, with foreign manufacturers holding a significant market share, indicating substantial potential for domestic product innovation[28]. - The company is focused on expanding its market presence through new product launches and technological advancements[62]. - The company aims to maintain a leading position in the international market through continuous innovation and patent acquisition[60]. - The market outlook for the new products is optimistic, with expectations of substantial growth post-launch[61]. - The company anticipates a market growth rate of 8.7% annually for stroke incidence in China, driven by an increasing prevalence of chronic diseases[72]. - The company is committed to improving patient outcomes through advanced medical technologies and innovative treatment solutions[71]. Risks and Challenges - The company faces risks related to the failure of new product development or delays in registration, particularly in high-risk medical devices, which could affect revenue and profitability growth[106]. - The company is at risk of talent loss if it cannot provide competitive compensation and a conducive work environment, which is critical for its development in a technology-driven industry[107]. - The company is exposed to risks from important raw material supply disruptions, as the required materials are sourced from a limited number of global suppliers[112]. - The company’s ability to maintain or improve product competitiveness is challenged by increasing competition in the cardiovascular intervention market[110]. - The company’s financial situation may be adversely affected by the inability to recover accounts receivable, particularly with aging receivables[119]. - The company is subject to risks from macroeconomic factors, including trade tensions and currency fluctuations, which could impact its overseas operations and overall performance[122]. Corporate Governance and Compliance - The company has committed to not engaging in any business that competes substantially with its operations, either directly or indirectly, through subsidiaries or controlled entities[162]. - The company has established a legal framework for its commitments, ensuring they are binding and enforceable[161]. - The company will distribute cash dividends of no less than 10% of the distributable profits achieved in the current year after reserving the statutory surplus and discretionary surplus funds[171]. - The company will ensure compliance with relevant laws and regulations regarding share reduction and will disclose reduction plans in advance[172]. - The company has no significant litigation or arbitration matters during the reporting period[187]. - The credit status of the company and its controlling shareholder is good, with no records of violations or significant tax offenses in the last three years[187].

Financial Performance - Sino Medical reported no cash dividends for 2021 due to significant adverse impacts from the centralized procurement policy for coronary stents, prioritizing future development funding needs[5]. - The company's operating revenue for 2021 was CNY 194,356,081.09, a decrease of 40.64% compared to the previous year[21]. - The net profit attributable to shareholders was CNY -130,765,690.12, representing a decline of 681.36% year-on-year[23]. - The cash flow from operating activities was CNY -60,133,405.36, down 185.28% from the previous year, primarily due to reduced revenue[23]. - Basic and diluted earnings per share were both CNY -0.32, a decrease of 740% compared to the previous year[22]. - The weighted average return on equity was -13.08%, a decrease of 15.15 percentage points year-on-year[22]. - The net profit after deducting non-recurring gains and losses was CNY -134,507,245.16, a decrease of 1,317.29% year-on-year[23]. - The company experienced a significant decline in main business income due to the implementation of centralized procurement policies for coronary stents, leading to a substantial drop in product prices[23]. - The company's main business revenue decreased by 40.51% year-on-year, primarily due to a 69.42% decline in stent product revenue, with sales volume dropping by 78.05%[160]. - The overall gross profit margin decreased by 6.08 percentage points, attributed to lower sales prices and reduced production scale due to the impact of centralized procurement policies[162]. Research and Development - The company is focused on product research and development, particularly in the area of biodegradable drug-coated coronary stent systems[5]. - Research and development expenses accounted for 95.37% of operating revenue, an increase of 46.75 percentage points from the previous year[22]. - The company invested CNY 185 million in R&D during the reporting period, an increase of 16.44% year-on-year, representing 95.37% of the 2021 revenue, up 46.75 percentage points from the previous year[36]. - The company added 16 new invention patents during the reporting period, with a total of 199 invention patents authorized and exclusive licenses globally[38]. - The company’s R&D personnel increased by 79.41% year-on-year, totaling 183 individuals by the end of the reporting period[36]. - The company has developed 8 key technologies and 18 product pipelines, with 16 new invention patents and 55 other intellectual property rights granted during the reporting period[71]. - The company is advancing the development of a unique thorn balloon that combines micro-cutting technology with balloon dilation, aimed at enhancing pre-dilation effects and treatment outcomes in coronary interventions[75]. - The company has established a complete independent core technology system in the cardiovascular and cerebrovascular intervention treatment fields, focusing on breakthroughs in key technologies and products[117]. Market Environment and Challenges - The company faced a challenging external operating environment, which was detailed in the risk factors section of the report[4]. - The national volume-based procurement policy initiated in October 2020 has altered the competitive landscape, impacting the company's market share due to its products not qualifying for the procurement[64]. - The company is focused on expanding its market presence in the coronary stent sector, despite facing challenges from national procurement policies[64]. - The domestic coronary intervention market is relatively mature, with significant room for domestic product substitution, driven by increased penetration of local manufacturers[62]. - The company faces risks related to new product development failures or delays, which could impact revenue and profitability growth[133][142]. - The company’s ability to maintain or improve market competitiveness is challenged by the ongoing centralized procurement policies and intense market competition[136][137]. - The company is exposed to risks from national procurement policies that could lead to significant price reductions for its products[146]. Governance and Compliance - The annual report includes a standard unqualified audit opinion from the accounting firm, ensuring the accuracy and completeness of the financial statements[5]. - The board of directors approved a profit distribution plan that reflects the company's current operational situation and future funding requirements for product development and market promotion[5]. - The board of directors consists of all members present at the meeting, affirming governance and decision-making processes[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[7]. Product Development and Innovation - The new generation drug-eluting stent system HT Supreme received EU approval and is undergoing clinical research in collaboration with National University of Ireland, Galway, involving 2,540 participants across six European countries[39]. - The company received regulatory approval for the world's first drug-eluting stent specifically designed for intracranial artery stenosis treatment, establishing a leading position in the ischemic neurology field[42]. - The company reported a significant breakthrough in the design of the Accufit interventional mitral valve replacement system, with improved survival rates and heart function recovery during animal trials[44]. - The company is developing a retractable, dual-stent, self-locking intervention mitral valve replacement technology, with multiple patents granted globally[78]. - The company’s NOVA intracranial drug-eluting stent system, the first of its kind for treating intracranial artery stenosis, received regulatory approval in July 2021, showing significant advantages in vascular healing and reducing restenosis compared to bare stents[77]. - The company has completed clinical trials for its new drug-eluting stent technology, which is expected to enhance treatment efficacy[26]. Human Resources - The company added 206 employees during the reporting period, a 43.19% increase year-over-year, including 81 new R&D personnel, reflecting a 79.41% growth in R&D staff[46]. - The number of R&D personnel increased by 81, a year-on-year growth of 79.41%, with master's degree and above personnel increasing by 13, a growth of 65%[116]. - Total compensation for R&D personnel reached 40.18 million RMB, compared to 27.40 million RMB in the previous period, with average compensation decreasing to 21.96 thousand RMB from 26.86 thousand RMB[118]. - The company emphasizes the importance of building a talent pool through internal training and high-level talent recruitment to support its rapid development[198]. Investment and Financial Strategy - The company invested $4 million to acquire an 18.2% stake in eLum Technologies, enhancing its innovation and R&D capabilities in the neurovascular intervention sector[45]. - The company plans to increase R&D and innovation efforts, aiming to enrich its product pipeline and accelerate the speed of new product launches[129]. - The company aims to balance domestic market risks by actively expanding into overseas markets, particularly for the HT Supreme stent in the US and Japan over the next two years[70]. - The company has invested RMB 10.50 million in working capital, exceeding the planned amount of RMB 10 million[194].

Financial Performance - Sino Medical reported no cash dividends for 2021 due to significant adverse impacts from the centralized procurement policy for coronary stents, prioritizing future development needs[5]. - The company faced a challenging external operating environment, which affected its financial performance and strategic planning[5]. - The company's operating revenue for 2021 was CNY 194,356,081.09, a decrease of 40.64% compared to the previous year[21]. - The net profit attributable to shareholders was CNY -130,765,690.12, representing a decline of 681.36% year-over-year[21]. - The cash flow from operating activities was CNY -60,133,405.36, down 185.28% from the previous year, primarily due to reduced revenue[23]. - Basic and diluted earnings per share were both CNY -0.32, a decrease of 740% compared to the previous year[22]. - The weighted average return on equity was -13.08%, a decrease of 15.15 percentage points year-over-year[22]. - The total assets at the end of 2021 were CNY 1,103,085,987.51, a decrease of 9.40% compared to the end of 2020[21]. - The net assets attributable to shareholders decreased by 13.92% to CNY 927,836,465.08 at the end of 2021[21]. - The company experienced a significant decline in sales due to the implementation of centralized procurement policies for coronary stents, leading to a sharp drop in product prices[23]. - In 2021, the company achieved a revenue of CNY 194 million, a decrease of 40.64% year-on-year, and a net profit attributable to shareholders of CNY -131 million, a decline of 681.36%[35]. - The company’s main business revenue decreased by 40.51%, with stent product revenue dropping by 69.42% due to significant price reductions from national centralized procurement policies, resulting in a sales volume decline of 78.05%[160]. - The overall gross profit margin decreased by 6.08 percentage points compared to the previous year, primarily due to lower sales prices and reduced production scale effects[162]. Research and Development - Sino Medical has not achieved profitability since its listing, indicating ongoing investment in product development and market expansion[4]. - The company is focused on the development of new products and technologies to enhance its market position[5]. - Research and development expenses accounted for 95.37% of operating revenue, an increase of 46.75 percentage points from the previous year[22]. - The company invested CNY 185 million in R&D during the reporting period, an increase of 16.44% year-on-year, representing 95.37% of the 2021 revenue, up 46.75 percentage points from the previous year[36]. - The company added 16 new invention patents during the reporting period, with a total of 199 invention patents authorized and exclusive licenses globally[38]. - The company is actively expanding its product categories and improving production quality and efficiency through lean manufacturing and smart manufacturing initiatives[35]. - Continuous R&D investment has led to the development of multiple key technologies and a robust product pipeline, ensuring sustained revenue growth[56]. - The company has established a comprehensive operational system covering product R&D, manufacturing, and sales, with a focus on high-end interventional medical devices[55]. - The company has developed 8 key technologies and 18 product pipelines, with 16 new invention patents and 55 other intellectual property rights granted during the reporting period[71]. - The company has established five technical platforms to support the development and production of neuro-interventional products, enhancing its capabilities in this field[76]. - The company has a multi-disciplinary R&D team with over 180 members, ensuring a strong foundation for continuous innovation[118]. Market Dynamics - The company is positioned to leverage the growing demand for interventional medical devices amid an aging population and increasing health awareness in China[59]. - The interventional medical device industry in China is supported by government policies aimed at promoting high-end medical device development, indicating a strategic national focus[59]. - The coronary intervention market is relatively mature, with significant potential for domestic product substitution, driven by increased competition and market penetration of local manufacturers[62]. - The national volume-based procurement policy initiated in 2020 has altered the competitive landscape of the coronary stent market, impacting the company's market share[64]. - The domestic neurointerventional market is still largely dominated by foreign brands, with low domestic replacement rates, indicating significant growth potential for local products[66]. - The grassroots medical market is expected to be a major growth point for medical device sales, with over 950,000 grassroots medical institutions in China as of November 2018[68]. - The market for neurointerventional products is largely dominated by foreign brands, indicating significant potential for domestic alternatives[106]. Regulatory and Compliance - The audit report issued by Lixin Accounting Firm confirmed the accuracy and completeness of the financial statements[5]. - The company is committed to maintaining long-term shareholder interests while navigating a complex regulatory landscape[5]. - There were no instances of non-operational fund occupation by controlling shareholders or related parties reported[7]. - The company has not violated decision-making procedures regarding external guarantees[7]. - The company is closely monitoring regulatory changes in the medical device industry to adapt its business strategies accordingly[148]. Operational Risks - The company has outlined various operational risks and corresponding mitigation strategies in its annual report[4]. - The company faces risks related to new product development failures or delays, which could impact revenue and profitability growth[132]. - The company is exposed to market competition risks, particularly in the neuro intervention sector, where foreign companies currently dominate the market[136]. - The company is at risk of talent loss if it cannot provide competitive compensation and a conducive work environment for its skilled workforce[133]. - The company faces potential impairment risks related to development expenditures and intangible assets if new products do not achieve effective sales post-launch[143]. Strategic Investments - The company made a strategic investment of 4 million USD in eLum Technologies, acquiring an 18.2% stake to enhance its innovation and R&D capabilities in the neurology sector[190]. - The company plans to accelerate its international market expansion, with an increasing proportion of overseas revenue as it seeks CE certification for its new generation HT Supreme drug-eluting stent[197]. - The company intends to broaden its product line through self-research and strategic partnerships, including acquisitions in the cardiovascular and neurovascular fields[198]. - The company plans to launch 30 research centers by April 2023 to enhance its product development capabilities in the neuro-interventional field[22].

2022 年第一季度报告 证券代码：688108 证券简称：赛诺医疗 赛诺医疗科学技术股份有限公司 2022 年第一季度报告 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 1 / 18 单位：元 币种：人民币 项目 本报告期 本报告期比上年同期增减变动幅度(%) 营业收入 59,092,563.59 113.27 归属于上市公司股东的 净利润 -29,398,472.91 28.81 归属于上市公司股东的 扣除非经常性损益的净 利润 -30,555,065.49 27.68 经营活动产生的现金流 量净额 -43,690,458.86 -30.55 基本每股收益 ...

Financial Performance - The company's operating revenue for Q3 2021 was ¥42,499,145.99, a decrease of 56.93% compared to the same period last year[5] - The net profit attributable to shareholders was -¥29,591,522.07, representing a decline of 267.44% year-on-year[5] - The basic earnings per share for the year-to-date period was -¥0.27, a decrease of 325.00% year-on-year[6] - The company reported a net loss of RMB 22,596,021.42 for the period, compared to a profit of RMB 88,537,713.00 in the previous year[17] - Total operating revenue for the first three quarters of 2021 was ¥121.13 million, a decrease of 56.0% compared to ¥275.12 million in the same period of 2020[20] - Net profit for the first three quarters of 2021 was a loss of ¥112.53 million, compared to a profit of ¥49.03 million in the same period of 2020[21] - The total comprehensive income for the first three quarters of 2021 was a loss of ¥113.22 million, compared to a gain of ¥48.25 million in 2020[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,097,759,942.46, down 9.83% from the end of the previous year[6] - As of September 30, 2021, the total assets of the company amounted to RMB 1,097,759,942.46, a decrease from RMB 1,217,497,750.16 as of December 31, 2020, representing a decline of approximately 9.8%[16] - The company's total current assets decreased to RMB 465,173,524.12 from RMB 723,433,818.99, reflecting a reduction of about 35.7%[15] - The total liabilities decreased to RMB 133,111,270.82 from RMB 139,630,293.64, a decline of about 4.0%[17] - The company's equity attributable to shareholders decreased to RMB 948,188,001.12 from RMB 1,077,867,456.52, a drop of approximately 11.9%[17] - Non-current liabilities increased to 47,454,613.25 RMB from 89,477,678.11 RMB, primarily due to the implementation of the new leasing standard[30] Cash Flow - The net cash flow from operating activities for the year-to-date period was -¥65,253,791.21, a decline of 201.62% compared to the previous year[6] - Operating cash flow for the first three quarters of 2021 was a net outflow of ¥65.25 million, contrasting with a net inflow of ¥64.21 million in 2020[25] - The net cash flow from financing activities was -41,040,839.56 RMB, indicating a significant outflow due to debt repayment and dividend distribution[26] - The cash and cash equivalents at the end of the period decreased to 280,526,833.35 RMB from 544,664,800.71 RMB at the beginning of the period, reflecting a net decrease of 264,137,967.36 RMB[26] Research and Development - Research and development expenses totaled ¥38,332,118.46, an increase of 3.70% compared to the same period last year, accounting for 90.20% of operating revenue[6] - Research and development expenses increased significantly to ¥108.74 million in 2021 from ¥74.45 million in 2020, marking a rise of 46.0%[20] Inventory and Other Assets - The company's inventory increased to RMB 79,088,470.52 from RMB 64,748,983.65, reflecting a rise of approximately 22.1%[16] - The company has ongoing investments in long-term equity amounting to RMB 25,573,665.32[16] - The company has a total of 82,067,762.90 RMB in intangible assets, which reflects ongoing investments in technology and product development[29] - The company’s other non-current assets totaled 6,338,644.14 RMB, indicating a stable asset base[29] Shareholder Information - The total equity attributable to shareholders was ¥948,188,001.12, down 12.03% from the previous year[6] - The company reported a total of 11,099 common shareholders at the end of the reporting period[13]